Cost-Effectiveness
Cost-Effectiveness
- Cost-Effectiveness of bevacizumab-based therapy versus
cisplatin+pemetrexed for the 1st line treatment of advanced non-squamous
NSCLC in Korea and Taiwan
Ahn MJ, Tsai C-M, Hsia T-C, Wright E, ChangJW-C, Kim HT, Kim J-H, Kang JH, Kim S-W, Bae J, Kang M, Lister J, Walzer S; Asia-Pacific Journal of Clinical Oncology 2011; 7 (suppl 2): 22-33
Cost-Effectiveness
- Health-economic
comparison of paricalcitol, calcitriol and alfacalcidol for the
treatment of secondary hyperparathyroidism during haemodialysis.
Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L. Clin Drug Investig 2006; 26(11):629-38.
Cost-Effectiveness
- Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary
Prevention and Nitrendipine in Secondary Prevention in Europe—The HEALTH
Model
Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener H-C,Lüders S,Schrader J, Antoñanzas Villar F,Greiner W, Jönsson B; Value in Health 12(6): 857-871
Cost-Effectiveness
- A Cross-Market Cost-Effectiveness Analysis of Erlotinib Versus Best
Supportive Care for First-Line Maintenance Treatment of Patients with
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with
Stable Disease
Vergnenègre A, Ray J, Chouaid C, Grossi F, Bischoff H, Heigener D, Walzer S; XXX2011: submitted
Online
PDF